← Back to Search

Behavioral Intervention

Communication Tool Adaptation for HIV Prevention (PrEP Trial)

N/A
Waitlist Available
Led By Mirjam-Colette Kempf, PhD, MPH
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Cisgender African American HIV-uninfected women aged 18 years or older who speak English and report HIV risk and/or recent PrEP use
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months and 12 months
Awards & highlights

PrEP Trial Summary

This trial will adapt and test a communication tool to increase PrEP uptake among at-risk African American women in rural areas of the southern US.

Who is the study for?
This trial is for African American, cisgender women over the age of 18 who speak English and are at risk for HIV but not infected. They should recognize their HIV risk or have used PrEP recently. Healthcare providers such as physicians, nurses, or social workers cannot participate.Check my eligibility
What is being tested?
The study aims to increase PrEP uptake among at-risk African American women in rural Alabama by adapting a communication tool from the CDC's PrEP toolkit. This tool will help with recognizing HIV risk and interest in starting PrEP through referrals to local clinics.See study design
What are the potential side effects?
Since this trial focuses on cultural adaptation of a communication tool rather than a medical intervention, traditional side effects associated with medications are not applicable here.

PrEP Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am an African American woman over 18, speak English, at risk for HIV or have used PrEP recently.

PrEP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Intervention acceptability
Intervention feasibility changes
PrEP uptake changes
Secondary outcome measures
Biological measures of HIV, STIs and pregnancy
Clinic visit adherence changes
PrEP adherence

PrEP Trial Design

1Treatment groups
Experimental Treatment
Group I: Cultural adaptation of a patient-provider communication toolExperimental Treatment1 Intervention
Strengthening of the PrEP care continuum by developing and testing an intervention designed to improve PrEP awareness, screening, engagement, retention, adherence, and persistence among individuals at substantial risk for HIV infection; developing and testing an intervention to reduce racial/disparities in PrEP uptake and use.

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,565 Previous Clinical Trials
2,268,233 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,774 Previous Clinical Trials
2,674,178 Total Patients Enrolled
Massachusetts General HospitalOTHER
2,918 Previous Clinical Trials
13,192,710 Total Patients Enrolled

Media Library

Cultural adaptation of a patient-provider communication tool (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04373551 — N/A
HIV/AIDS Research Study Groups: Cultural adaptation of a patient-provider communication tool
HIV/AIDS Clinical Trial 2023: Cultural adaptation of a patient-provider communication tool Highlights & Side Effects. Trial Name: NCT04373551 — N/A
Cultural adaptation of a patient-provider communication tool (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04373551 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current status of recruitment for this clinical trial?

"Per the information on clinicaltrials.gov, enrollment in this trial has been closed since June 13th 2022 - though it was initially posted April 14th 2020. However, 1185 other trials are actively recruiting patients at present."

Answered by AI
~7 spots leftby Jun 2024